Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer

Abstract Therapeutic anti-PD-L1 antibodies are safe as a monotherapy, albeit with minimal efficacy in triple-negative breast cancer (TNBC). This trial aimed to test the safety and efficacy of Durvalumab and Paclitaxel in metastatic TNBC. In this open-label, one-arm trial, five cycles of weekly pacli...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hazem Ghebeh, Adher Al-Sayed, Riham Eiada, Leilani Cabangon, Dahish Ajarim, Kausar Suleman, Asma Tulbah, Taher Al-Tweigeri
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/4082da344ce44ce6b8b8a7859e11152b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!